Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 2,054.18 ($27.58) and traded as high as GBX 2,086 ($28.00). Hikma Pharmaceuticals shares last traded at GBX 2,068.16 ($27.76), with a volume of 410,972 shares.
Wall Street Analyst Weigh In
Several research analysts have weighed in on HIK shares. Berenberg Bank restated a "buy" rating and set a GBX 2,560 ($34.37) price objective on shares of Hikma Pharmaceuticals in a report on Monday, March 10th. JPMorgan Chase & Co. restated an "overweight" rating on shares of Hikma Pharmaceuticals in a report on Friday, March 7th.
Get Our Latest Stock Report on Hikma Pharmaceuticals
Hikma Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The company's fifty day simple moving average is GBX 2,027.34 and its two-hundred day simple moving average is GBX 2,056.35. The stock has a market cap of £5.74 billion, a price-to-earnings ratio of 20.31, a P/E/G ratio of 2.38 and a beta of 0.41.
Insiders Place Their Bets
In other news, insider Victoria Hull sold 2,777 shares of the stock in a transaction dated Tuesday, April 8th. The shares were sold at an average price of GBX 1,800 ($24.16), for a total value of £49,986 ($67,104.31). Also, insider Said Darwazah sold 13,863 shares of the stock in a transaction dated Friday, May 30th. The shares were sold at an average price of GBX 2,138 ($28.70), for a total transaction of £296,390.94 ($397,893.60). Corporate insiders own 30.54% of the company's stock.
Hikma Pharmaceuticals Company Profile
(
Get Free Report)
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.
Further Reading
Before you consider Hikma Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.
While Hikma Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
